Tom Ruggia, President and CEO of Samsara Vision, provides updates on the lead asset for late-state age-related macular degeneration: Smaller-incision, new generation, implantable miniature telescope (SING IMT).
Note: This transcript has been lightly edited for clarity.
Tom Ruggia: Hello, I'm Tom Ruggia, President and CEO of Samsara Vision.
At Samsara Vision, we are innovating to bring freedom and vision back to patients with late-stage age-related macular degeneration. We're doing that with our lead asset: The SING IMT, or the Smaller Incision New Generation Implantable Miniature Telescope. This device has now been implanted in almost 100 patients worldwide, commercially available in Europe and developing in Asia Pacific.
We have begun our Concerto trial, a PMA supplement trial, designed to get approval in the United States in due course, but we are recruiting patients now for the Concerto trial in the United States. The patient journey has been wonderful with our almost first 100 patients. We've got remarkable patient stories. You can see those on our website at samsaravision.com.